Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with nasopharyngeal carcinoma (a type of nose and throat cancer).
- Your EBV DNA level is still detectable in the blood 1 week to 4 weeks after completing radiation therapy.
- Your overall health is good (ECOG score 0 or 1) and you are expected to live at least 12 weeks.
- You have normal or near-normal organ functions as measured by blood tests.
- You have not had other cancers in the last 5 years, except for certain early skin or cervical cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of the immunotherapy drug tislelizumab combined with standard chemotherapy and radiation for a specific type of nasopharyngeal cancer. It aims to see if this approach is safe and effective for patients with advanced-stage disease.
This trial tests if an immunotherapy drug (adebrelimab) can help people with advanced nasopharyngeal cancer whose Epstein-Barr virus (EBV) DNA levels stay high or stable after initial chemotherapy. It aims to see if this personalized approach improves outcomes.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.